Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Friday. The brokerage set a “sell” rating on the stock.

Oragenics Price Performance

Shares of NYSE OGEN opened at $0.39 on Friday. The stock’s fifty day moving average price is $0.80 and its two-hundred day moving average price is $1.19. Oragenics has a one year low of $0.35 and a one year high of $7.74. The firm has a market cap of $1.73 million, a price-to-earnings ratio of -0.05 and a beta of 0.45.

Oragenics (NYSE:OGEN) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics at the end of the most recent reporting period. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.